Cyclophosphamide/doxorubicin/paclitaxel Reactions 1680, p102 - 2 Dec 2017 Cyclophosphamide/doxorubicin/ paclitaxel Vitiligo: case report A woman in her 50s [exact age at reaction onset not stated] developed vitiligo during treatment with cyclophosphamide, doxorubicin [adriamycin] and paclitaxel. The woman had a history of hypothyroidism treated with thyroxine replacement therapy. She was diagnosed with breast cancer along with an axillary lymphadenopathy at the age of 58 years, and underwent left modified radical mastectomy. Subsequently, she received 4 cycles of chemotherapy with 2 2 cyclophosphamide 600 mg/m and doxorubicin 60 mg/m , followed by four cycles of paclitaxel 175 mg/m [routes not stated]. After completion of 24 week chemotherapy course, she was treated with an external beam radiotherapy to the left chest wall. Approximately nine months after radiotherapy, she was observed with a depigmentation on the left chest wall, which was congruent with area of radiation delivery. The hypopigmented lesions could be identified with sharp margins. The lesions were without a definite shape, which coalesced and persisted as evidenced in her successive follow- ups. At the last follow up, the woman was found to be well, though continued with hypopigmented lesions on the left chest, without any further regression or progression. Author comment: "It is not clear whether addition of chemotherapy contributed to the development of hypopigmentation, but it was likely a risk factor." Pavithran K, et al. Report of a case of radiation-induced new-onset vitiligo with collective review of cases in the literature of radiation-related vitiligo. Case Reports in Medicine 2013: 2013. Available from: URL: http:// - India 803284146 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial